1 in 4 people will be diagnosed with cancer in his lifetime

Did you know that the general risk of developing cancer in one's lifetime (from birth to death) is an alarming 25%? That is, statistically, 1 in 4 people will be diagnosed with cancer (that's 1 in almost every family) at least once. With the GLOBOCAN 2022 statistics, by the year 2050, we will witness an alarming 75-80% increase of 35 million predicted new cases. These cancer statistics are alarming! It is vital for every person to understand the gaps and issues in the humanitarian concern of cancer. Don't let yourself be restricted by a standard medical procedure. Do your research and explore all your options, and you will learn that cancer treatments and chemotherapy is not "one fit all" anymore and it is actually improving and making a difference to the civilized world we live in. We will not deny that not every cancer will be curable and not every tumour will respond to treatment. However, we do believe that cancer treatments should always be initiated early as possible with the most suited and focused treatment.

The rapid advancement of technology means that the field of oncology is continually evolving. For those suffering from cancer, this is life-changing. More options will likely mean an extended lifespan. More digital technology will help oncologists provide a more tailored healthcare experience.

When a cancer patient arrives at a clinic, one of the hurdles that the healthcare providers face is that the patient has already been through a journey that has altered their body in a way that is unique. Therefore, responding to their needs is very difficult. OMICS, advanced digital technology, and artificial intelligence can be the healthcare industry game changers.

Treatment analytics in the OmixMe platform has integrated user and patient data while also collaborating with bioinformatics and oncological experts. This helps doctors understand the patient in a way that no other platform has been able to provide. This helps doctors understand patient data and make better decisions, as well as providing more tailored care and reducing side effects.

The OmixMe labs perform cancer treatment customization in a multi-layered and advanced state. The first step to customizing treatment is performing an extremely detailed analysis of the cancer and using that to help further build the technology. Many advanced OMICS technologies aid in the analysis, and a lot of data is then processed using artificial intelligence in order to prepare and help choose the treatment options.

Experts say the future of oncology will not only focus on advancements in pharmacology but also in informatics. Digital innovations of the present day allow the measurement of different types of data in real time. This equips doctors with the ability to make better decisions and actually reduces the time treatment takes and the time patients have to wait to receive treatment that is more specific and better suited to individual needs.

Miroslav Chovanec of the Institute of Experimental Oncology said the following:

"The integration of multi-OMICS data with artificial intelligence captures the first step in an era of cancer treatment that is tailored not only to the individual, but one which can also be flexible to cater to the individual needs of the patient on a continual basis."

The randomised ROME study indicated that the introduction of genomically guided therapy, which is based on a highly developed dosage based on targeted genetic data, achieved a positive response of a solid tumour in 17.5% of patients. This is a 7.5% improvement to the previous method in which the majority of patients did not achieve a positive response, with a success rate of only 10%. When treatment was tailored to the individual 22% of patients achieved a positive response and remained free of progression of the disease for 12 months. This is an improvement of 13.7% for the standard treatment in which only 8.3% of patients remained free of progression of the disease after 12 months.

It is important that the novel technology of whole genome sequencing (WGS) has advanced to the point where it can provide clinically meaningful and clinically actionable results that can be offered to an estimated 42% of patients. Success, however, is also highly dependent on the type of tumour and the available therapy. Diverse Omics technologies further bridge the gap between the understanding of cancer and the selection of effective therapies, thereby leading to therapies that better match and target the individual.

In the EXALT study, where functional drug testing using patient tumour cells was conducted, substantial promise was also shown. In patients with blood cancer and those with more aggressive tumours, both clinical and functional outcomes were enhanced in almost 54% of the participants.

The OmixMe platform's analyses basically centre on more hope being allowed — and in the field of medicine, this hope along with the promise of a better existence comes from the advancement of therapeutic assist technologies.